Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer-Fighting virus trial for breast cancer pulled before it began

NCT ID NCT07150767

Terminated Disease control Sponsor: Beijing Bio-Targeting Therapeutics Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial aimed to test a new virus-based drug called BioTTT001, injected directly into tumors, alongside standard pre-surgery treatment for women with locally advanced breast cancer. The goal was to see if the combination was safe and could shrink tumors. However, the study was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BioTTT001 (a modified virus injected into tumors to stimulate the immune system)
What this could lead to
If successful, this approach could offer a new way to shrink tumors before surgery for locally advanced breast cancer.
What could go wrong
The trial was withdrawn before any patients enrolled, so no data exists. Early-phase virus therapies can cause flu-like side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BREAST CANCER (LABC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED BREAST CANCER (LABC)

Contacts and locations

Locations

  • The Second People's Hospital of Shandong Province

    Jinan, Shandong, 250022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.